Business Wire

MA-ACCESS-ADVANCE

9.3.2022 01:02:11 CET | Business Wire | Press release

Share
Access Advance Addresses Düsseldorf Court Ruling, Announces Revised Duplicate Royalty Policy for the HEVC Advance Patent Pool

Access Advance, an independent licensing administrator, today announced that the licensors to its HEVC Advance Patent Pool approved a revised Duplicate Royalty Policy. The revised Policy responds to the Düsseldorf District Court’s December 21, 2021 ruling, which declined to grant an injunction despite finding Vestel Germany GmbH (“Vestel”) liable for damages arising from its infringement of certain HEVC standard essential patents asserted by HEVC Advance licensors.

While Access Advance’s Duplicate Royalty Policy followed (and exceeded) long-standing industry practice, because of the substantial number of overlapping patents in the HEVC Advance Patent Pool and MPEG LA's HEVC patent pool to which Vestel was licensed (as a result of Vestel taking an MPEG LA license in 2018 before a large number of licensors left MPEG LA), the German court found such practice not FRAND. In particular, the court found such practice (1) did not impose on the HEVC Advance Patent Pool a direct legal obligation to Vestel ensuring that a licensor whose patents were licensed in both pools did not receive a duplicate royalty payment, and (2) did not adequately specify to Vestel prior to license execution the methodology each licensor would apply to prevent receipt of such duplicate royalties by licensors.

Importantly, the court once again did not express concerns with any other facet of the HEVC Advance Patent Pool, including its royalty rates. In an earlier set of patent infringement cases brought by several HEVC Advance Patent Pool licensors against MAS Elektronik, this same court expressly confirmed that the HEVC Advance pool license and rates were FRAND. Nothing about the court’s Vestel decision changes or undermines this prior and fundamental finding.

The revised Policy announced today not only resolves the issues identified by the court, but goes a significant step further in allowing licensees under both the HEVC Advance Patent Pool and another HEVC patent pool or joint licensing program that qualify to elect to receive a deduction from the HEVC Advance Patent Pool for the amount of duplicate royalties that would be received by HEVC Advance licensors on account of patents licensed under both the HEVC Advance Patent Pool and the other HEVC patent pool or joint licensing program. Previously, each HEVC Advance licensor could determine from which pool or program a licensee would receive a duplicate royalty deduction.

Details of the revised Duplicate Royalty Policy and the related Duplicate Royalty Adjustment Amendment to the HEVC Advance Patent Portfolio License and Duplicate Royalty Estimate Request can be found at: https://accessadvance.com/licensing-programs/hevc-advance/ .

About Access Advance:

Access Advance LLC (formerly HEVC Advance LLC) is an independent licensing administrator company formed to lead the development, administration, and management of patent pools for licensing essential patents of the most important standards-based video codec technologies. Access Advance provides a transparent and efficient licensing mechanism for both patent owners and patent implementers. Access Advance currently manages and administers the HEVC Advance Patent Pool for licensing patents essential to H.265/HEVC technology, and the separate and independent VVC Advance Patent Pool for licensing essential patents to VVC/H.266 technology. For more information about Access Advance, the HEVC Advance Patent Pool, or the VVC Advance Patent Pool, please visit www.accessadvance.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye